Sialosyl-Tn Antigen in Gastric Cancer and Its Impact on Survival
Author Information
Author(s): J.L. Werther, S. Rivera-MacMurray, H. Bruckner, M. Tatematsu, S.H. Itzkowitz
Primary Institution: Mount Sinai School of Medicine
Hypothesis
The study investigates the correlation between sialosyl-Tn antigen expression in gastric cancer and patient outcomes.
Conclusion
Sialosyl-Tn antigen expression is associated with a significantly worse prognosis in gastric cancer patients.
Supporting Evidence
- 68% of gastric cancers expressed sialosyl-Tn antigen.
- 81% of patients with STn-positive tumours died or had recurrent cancer.
- Only 20% of patients with STn-negative tumours experienced the same adverse outcomes.
Takeaway
If a patient has a certain marker called sialosyl-Tn in their stomach cancer, they are more likely to have a bad outcome compared to those who don't have it.
Methodology
The study evaluated sialosyl-Tn antigen expression in gastric cancer tissues using immunohistochemistry and correlated it with clinical outcomes.
Limitations
Complete staging information was not available for some patients.
Participant Demographics
The study included 31 patients, with 11 non-Caucasian individuals (4 black, 4 Hispanic, 3 oriental).
Statistical Information
P-Value
<0.002
Statistical Significance
p<0.002
Want to read the original?
Access the complete publication on the publisher's website